Results 21 to 30 of about 2,386,530 (346)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis [PDF]

Critical Care, 2018
Debasree Banerjee, Sean Monaghan, Runping Zhao, Thomas Walsh, Amy Palmisciano, Gary S. Phillips, Steven Opal, Mitchell M. Levy   +7 more
doaj   +3 more sources

Regulation of Neuroinflammation through Programmed Death-1/Programmed Death Ligand Signaling in Neurological Disorders [PDF]

Frontiers in Cellular Neuroscience, 2014
Immune responses in the central nervous system (CNS), which involve both resident glial cells and infiltrating peripheral immune cells, play critical roles in the progress of brain injuries and neurodegeneration.
Shangfeng eZhao, Shangfeng eZhao, fengwu eli, Rehana K Leak, Jun eChen, Xiaoming eHu, Xiaoming eHu   +6 more
doaj   +3 more sources

Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma [PDF]

Clinical Cancer Research, 2016
Abstract Purpose: The immune checkpoint of the programmed death 1/programmed death ligand 1 (PD-1/PD-L1) pathway is believed to play an important role in evasion of host antitumor immune surveillance in various malignancies; however, little is known about its role in thymic carcinoma.
Shintaro, Yokoyama, Hiroaki, Miyoshi, Kazutaka, Nakashima, Joji, Shimono, Toshihiro, Hashiguchi, Masahiro, Mitsuoka, Shinzo, Takamori, Yoshito, Akagi, Koichi, Ohshima   +8 more
openaire   +2 more sources

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. [PDF]

Journal of Clinical Oncology, 2016
PurposeExpression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti–programmed death 1 (PD-1). This study explored the relationship between anti–PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 ...
A. Daud, J. Wolchok, C. Robert, W. Hwu, J. Weber, A. Ribas, F. Hodi, A. Joshua, R. Kefford, R. Kefford, R. Kefford, P. Hersey, R. Joseph, T. Gangadhar, R. Dronca, A. Patnaik, H. Zarour, C. Roach, Grant Toland, J. Lunceford, Xiaoyun Li, K. Emancipator, M. Dolled-Filhart, S. Kang, S. Ebbinghaus, O. Hamid   +25 more
semanticscholar   +5 more sources

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression [PDF]

Journal of Pathology and Translational Medicine, 2017
Background Glucose transporter type 1 (GLUT1) expression is linked to glucose metabolism and tissue hypoxia. A recent study reported that GLUT1 was significantly associated with programmed death ligand 1 (PD-L1) as a therapeutic target in relapsed or ...
Young Wha Koh, Jae-Ho Han, Seong Yong Park, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh   +5 more
doaj   +1 more source

Assessment of PD-L1 expression in patients with neuroblastoma and renal tumors

The Turkish Journal of Pediatrics, 2021
Background. Programmed death 1 (PD-1) is a co-receptor which is located at the surface of cells like natural killer, monocytes, T and B cells. It has two ligands including programmed death ligand-1 (PD-L1) and ligand-2 (PD-L2).
Seher Şener, Aylar Poyraz, Arzu Okur, Faruk Güçlü Pınarlı, Ceyda Karadeniz   +4 more
doaj   +1 more source

Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.

JAMA dermatology, 2022
Importance Despite the efficacy of immune checkpoint inhibitors (ICIs), cutaneous immune-related adverse events (cirAEs) occur in 20% to 40% of all treated patients.
K. Tang, J. Seo, Bruce C Tiu, T. Le, V. Pahalyants, N. Raval, P. Ugwu-Dike, L. Zubiri, V. Naranbhai, Mary Carrington, A. Gusev, K. Reynolds, N. Leboeuf, M. Asgari, S. Kwatra, Y. Semenov   +15 more
semanticscholar   +1 more source

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

Journal of Clinical Oncology, 2018
PURPOSE Treatment with programmed cell death-1 or programmed death ligand 1 (PD-(L)1) inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive effect of corticosteroids may reduce efficacy of PD-(L)1 blockade.
K. Arbour, L. Mezquita, N. Long, H. Rizvi, É. Auclin, A. Ni, G. Martínez-Bernal, R. Ferrara, W. Lai, L. Hendriks, J. Sabari, C. Caramella, A. Plodkowski, D. Halpenny, J. Chaft, D. Planchard, Gregory Riely, B. Besse, M. Hellmann   +18 more
semanticscholar   +1 more source

Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy

Frontiers in Immunology, 2021
Although various immunotherapies have exerted promising effects on cancer treatment, many patients with cancer continue to exhibit poor responses. Because of its negative regulatory effects on T cells and its biological functions related to immune and ...
Y. Qi, Li Chen, Qiang Liu, X. Kong, Yi Fang, Jing Wang   +5 more
semanticscholar   +1 more source

Programmed death-1 (PD-1) ligand 1 and PD-1 ligand 2 expressions and their clinical relevance in colorectal cancer [PDF]

Korean Journal of Clinical Oncology, 2017
Purpose Programmed death-1 and its ligands (PD-L1 and PD-L2) can induce T-cell apoptosis in many solid tumors, although there is limited information regarding their roles in colorectal cancer.
Jee Hyun Ahn, Hyun Yong Lee, Dong Hyun Kang, Geum Jong Song, Tae Sung Ahn, Myoung Won Son, Moon Soo Lee, Moo-Jun Baek   +7 more
doaj   +1 more source